AGIOS PHARMACEUTICALS, INC. OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax
AGIOS PHARMACEUTICALS, INC. (AGIO) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax of $1.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2026-06-30 was $1.48M.
- AGIOS PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2026-03-31 was $2.51M.
- AGIOS PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2025-09-30 was -$1.40M.
- AGIOS PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2025-06-30 was -$290.00K.
- AGIOS PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for fiscal 2025 was -$3.71M, a 444.57% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for fiscal 2024 was $1.08M.
- AGIOS PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for fiscal 2023 was -$12.09M, a 206.68% decline from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for fiscal 2022 was $11.34M, a 770.07% increase from fiscal 2021.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.48M 10-Q · filed 2026-07-30 | $3.99M derived: sum of 2 quarters · filed 2026-07-30 | |||
| 2026-03-31 | $2.51M 10-Q · filed 2026-07-30 | ||||
| 2025-12-31 | -$3.71M 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | -$1.40M 10-Q · filed 2025-10-30 | -$1.69M derived: sum of 2 quarters · filed 2026-07-30 | -$3.57M derived: sum of 3 quarters · filed 2026-07-30 | ||
| 2025-06-30 | -$290.00K 10-Q · filed 2026-07-30 | -$2.17M derived: sum of 2 quarters · filed 2026-07-30 | |||
| 2025-03-31 | -$1.88M 10-Q · filed 2026-07-30 | ||||
| 2024-12-31 | $1.08M 10-K · filed 2026-02-12 | ||||
| 2024-09-30 | -$4.46M 10-Q · filed 2025-10-30 | -$4.51M derived: sum of 2 quarters · filed 2025-10-30 | -$3.86M derived: sum of 3 quarters · filed 2025-10-30 | ||
| 2024-06-30 | -$42.00K 10-Q · filed 2025-10-30 | $604.00K derived: sum of 2 quarters · filed 2025-10-30 | |||
| 2024-03-31 | $646.00K 10-Q · filed 2025-10-30 | ||||
| 2023-12-31 | -$12.09M 10-K · filed 2026-02-12 | ||||
| 2023-09-30 | -$2.97M 10-Q · filed 2024-10-31 | -$2.52M derived: sum of 2 quarters · filed 2024-10-31 | -$6.64M derived: sum of 3 quarters · filed 2024-10-31 | ||
| 2023-06-30 | $459.00K 10-Q · filed 2024-10-31 | -$459.00K 10-Q · filed 2023-08-03 | -$3.67M derived: sum of 2 quarters · filed 2024-10-31 | ||
| 2023-03-31 | -$4.12M 10-Q · filed 2024-10-31 | $4.12M 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $11.34M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $4.58M 10-Q · filed 2023-11-02 | $7.34M derived: sum of 2 quarters · filed 2023-11-02 | $13.88M derived: sum of 3 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $2.76M 10-Q · filed 2023-11-02 | -$2.76M 10-Q · filed 2023-08-03 | $9.30M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $6.55M 10-Q · filed 2023-11-02 | -$6.55M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $1.30M 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |